LANARKSHIRE AREA DRUG & THERAPEUTICS COMMITTEE

Minute of the meeting held on Wednesday 18th January 2017 at 10am in the Board Room, Kirklands

PRESENT:  
Dr Mehrdad Malekian [Chair]  
Mr John Milne  
Mr George Lindsay  
Miss Katrina Mackie  
Mrs Gail Richardson  
Dr Vijay Sonthalia  
Dr Stephanie Dundas  
Ms Linda Johnstone  
Mrs Karen Patterson  
Mrs Anne Milne  
Dr Al Waly Majumdar  
Mr Bill Angus  
Mrs Mary Gilfillan

2017/001  
Apologies

Dr Harpreet Kohli, Mrs Christine Gilmour, Ms Anne Auld

2017/002  
Declaration of interest

Dr Malekian asked if anyone had an interest to declare for any items being discussed today. No-one indicated that they had any interests to declare.

2017/003  
Matters Arising not covered elsewhere on the agenda

(a) Ratification of Minutes of 21st December 2016

The minutes were accepted as a true record of the meeting with the following points:

- Mrs Patterson confirmed that under 2016/177(c), it had been suggested that a locum Psychiatrist was discussing the Guidance on Vitamin Supplementation in Alcohol Abuse. It was confirmed that the Psychiatrist is in a substantive post in addictions.
- Under 2016/177(g) Insulin Patient Safety Alert, there is no action point from this discussion.
- On page 4, the word ‘liase’ should be changed to ‘liaise’.

(b) Desmopressin update

In the absence of Mrs Gilmour, this would be deferred to the February 2017 meeting.

(c) New NHSL Creon guidance update

Dr Malekian fed back on the three points mentioned in the November 2016 minute. The Committee were satisfied that all had been satisfactorily dealt with and it was agreed that Dr Malekian will feed back to the authors that we can now proceed.

(d) Nalmefene update
Miss Mackie indicated that there is a willingness to reform a short life working group with many of the original members being prepared to take part again. This will be done and Miss Mackie will feed back to the ADTC in due course. Meantime, it does not need to be a recurring item each month.

(e) Montgomery review

In the absence of Mrs Gilmour, this would be deferred to the February 2017 meeting.

(f) Review of information on PPI leaflet

Mrs Milne indicated that she has emailed the doctor who expressed initial concern asking for the detail but no such detail has been forthcoming. In addition, she confirmed that all summary of product characteristics indicate the risk for bone fracture with PPI's so the Committee agreed that we can continue with the leaflet giving this information.

(g) Response to medicines benefits and risks leaflet

Mr Lindsay talked through the feedback which had now been provided to the Area Drugs and Therapeutics Committee Collaborative and an acknowledgement has been received.

2017/004 SMC NEW Submissions – Confidential until 13th February 2017

FULL SUBMISSIONS

Osimertinib (Tagrisso®) (No.1214/17)
This was noted and feedback will come from the West of Scotland Cancer Network.

Everolimus (Afinitor®) (No.1215/17)
This was noted and feedback will come from the West of Scotland Cancer Network.

Trifluridine, tipiracil (Lonsurf®) (No.1221/17)
This was noted and feedback will come from the West of Scotland Cancer Network.

Desmopressin oral lyophilisate (Noqdima®) (No. 1218/17)
This was noted.

RESUBMISSIONS

Evolocumab (Repatha®) (No.1148/16)
This was noted and will be referred to Cardiology specialists.
Iron (III) isomaltoside 1000 (Diafer®) (No.1177/16)
This was noted and will be referred to Renal specialists.

Botulinum toxin type a (BOTOX®) (No.692/11)
This was noted and will be referred to Neurology specialists.

NON SUBMISSIONS

Pitolisant (Wakix®) (No. 1229/17)
This was noted.

Vernakalant (Brinavess®) (No. 1222/17)
This was noted.

AMENDED ADVICE

Elbasvir-grazoprevir (Zepatier®) SMC No 1203/17
This was noted.

Pembrolizumab (Keytruda®) SMC No 1204/17,
This was noted.

2017/005  SMC follow-up
Miss Mackie talked the committee through the SMC follow-up which had been previously circulated. Further advice from Haematology specialists will be requested, before a decision on Deferasirox (Exjade®) formulary status can be made.  

2017/006  Lanarkshire formulary
Nil to note.

2017/007  Clinical protocols
a.  Splenectomy guidelines

There was a useful discussion which identified that a point of detail with regard to the precise Pneumococcal vaccine to use for patients aged 2 to 11 needs to be clarified.

In addition, we discussed that the guideline had a therapeutic component which will be a matter of fact and a process component which will detail which healthcare professionals are responsible for each element of delivering the care whether it be for an elective on an emergency splenectomy. It was agreed that Dr Dundas/Gail Richardson will feed back to Rebecca Ritchie, the lead author, the points of clarification required with regard to the therapeutics and George Lindsay will liaise with David Cromie and Jim White in public health, with a request that they chair a short life working group consisting of all stakeholders who would be interested in this
clinical area to clarify the responsibilities of each member of the healthcare team.

2017/008 ADTC Bulletin

The ADTC Bulletin (No. 111) for December 2016 was noted.

2017/009 Unlicensed Medicines

Mr Lindsay and Mrs Patterson discussed that there may be problems with accessing licensed Disulfiram in the near future. Previously, this has been challenging within the UK and our ADTC supported the use of imported Disulfiram 500mg strength. It was agreed that if we need to re-enact that scenario for this current shortage, then the ADTC are happy to support it.

2017/010 NICE/HIS Guidance

There was nil to note at this meeting.

2017/011 Medication and clinical risk in NHS Lanarkshire

This was noted.

2017/012 Regional Cancer Advisory Network

Mr Milne talked through the extensive and impressive protocols produced by the RCAG.

Mrs Milne indicated that while the protocol for the use of LHRH suggested that patients already established would not change, there was scope for local variation on this and the intention in NHS Lanarkshire was that the opportunity for change should exist.

2017/013 Patient Safety Alerts

There was nil to note at this meeting.

2017/014 Lay member related items

There was nil to note at this meeting.

2017/015 Correspondence

a. ADTC Collaborative

i. Standard template for new medicines decisions

This was noted.

ii. Mapping of IPTR and PACS processes

Dr Malekian will liaise with Mrs Gilmour and Dr Burns to make sure that this is completed for NHS Lanarkshire.
**2017/016 Any Other Business**

a. **DOACs**

Miss Mackie gave feedback about the formation of a national group seeking to find a consensus on the use of DOACs for atrial fibrillation. The expectation is that there will be one of the DOACs promoted as a preferred choice throughout Scotland. Further work, via Health Improvement Scotland, is being carried out to assess all four DOACs in terms of:

- Safety
- Efficacy
- Cost
- Ease of use

We debated representation from NHS Lanarkshire on this group and concluded that Miss Mackie should continue to represent NHS Lanarkshire being supported by the ADTC and other clinicians with an interest in this matter.

b. **Apixaban checklist**

Mrs Patterson reminded the committee that a checklist for Rivaroxaban had previously been endorsed by this Committee and asked if a similar document for Apixaban should be brought to the Committee. It was agreed that this should be done for the February meeting.

KP

c. **Vitamin B Co Strong**

Mrs Patterson indicated that the continued use of this medication outwith protocol was continuing by a particular consultant. The issue had been escalated to the Clinical Director and Associate Medical Director for mental health. It is anticipated that there will be a further discussion about it within the next week or two and Mrs Patterson will feedback to the ADTC.

KP

In addition, Dr Sonthalia suggested that further dissemination of the new guidance would be useful to all GP’s and Community Pharmacists and Mrs Milne indicated that this will happen in the next edition of Prescribing Notes.

d. **Ways of working**

Dr Malekian indicated that given we are into a new year, it is a useful time to reflect on the work and methods of ADTC and he encouraged all members to feed back if they feel there is a better way of the Committee working.

All

He also indicated that we have not yet had a replacement for Dr Colin Ooi and he asked Dr Sonthalia and Dr Al Waly Majumdar to give this some consideration.

DS/AWM

He also indicated some of the difficulties that there are in getting consultant
staff from the Acute Service but he will continue to try. MM

Mr Angus asked if it would be useful to include someone from the South Lanarkshire Carers Network and this will be given consideration. All

2017/017 Date of Next Meeting

The next scheduled meeting is on Wednesday 22\textsuperscript{nd} February 2017 at 10am in the Board Room, Kirklands.